The Aim of This Project is to Verify Whether a Depletion of B Cell Memory Subpopulation ("Marginal-zone-like") CD19 + IgD + CD27 + and CD19 + IgM + CD27 + is a Useful Indicator of Hyposplenism in Patients With Celiac Disease
NCT03763487 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50
Last updated 2018-12-04
Summary
This project is expected to confirm the hypothesis that hyposplenism in patients with celiac disease is not conditioned by a selective memory deficiency of B lymphocytes.
Other objectives of project are:
* determination of gliadin 33-mer in faecal and urine as indicators patient´s adherence to gluten-free diet
* determination of citrulline in plasma as an indicator of the overall functional capacity enterocytes
Conditions
Interventions
- DIAGNOSTIC_TEST
-
venous blood sampling
Venous blood samples to determine memory B lymphocytes.
- PROCEDURE
-
spleen volumetry
Ultrasound examination of spleen to scaled the size.
Sponsors & Collaborators
-
University Hospital Hradec Kralove
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-06-01
- Primary Completion
- 2018-12-31
- Completion
- 2018-12-31
Countries
- Czechia
Study Locations
More Related Trials
-
T Cell Receptor (TCR) Sequencing and Transcriptional Profiling in Adult Celiac Disease Patients Undergoing Gluten Challenge
NCT04614571 ·Status: COMPLETED ·Phase: NA
-
Rapid Technique for the Detection of Intestinal Anti-transglutaminase Antibodies
NCT05786183 ·Status: UNKNOWN
-
Detection of Immunotoxic Gluten Peptides in Feces
NCT01478867 ·Status: COMPLETED
-
Serological Identification of Celiac Disease in Kids
NCT03966625 ·Status: COMPLETED
-
Mass Screening for the Early Detection of Patients With Celiac Disease.
NCT05186038 ·Status: COMPLETED
-
Evaluation of Patient Reported Outcome Instruments in Celiac Disease Patients
NCT01560169 ·Status: COMPLETED
-
Gluten-free Diet in Gluten-genetically Predisposed Subjects
NCT00677495 ·Status: COMPLETED ·Phase: NA
-
Assessment of Coeliac Disease in Patients With Type 2 Diabetes
NCT06283264 ·Status: NOT_YET_RECRUITING
-
Impact of Gluten Contamination in Celiac Patients Clinically Responsive and Unresponsive to the Gluten-free Diet
NCT05066191 ·Status: UNKNOWN
-
A Study to Evaluate Gluten Challenge on Immune Responses in Subjects With Celiac Disease
NCT03521180 ·Status: COMPLETED
-
Immunosafe-CeD: Are Partially Hydrolysed Gluten Harmful to Celiac Disease Patients?
NCT06151782 ·Status: COMPLETED ·Phase: NA
-
Gluten-free Diet Monitoring in Urine
NCT02344758 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
No-biopsy Approach in Celiac Disease: Cut-off Points for IgA Anti-tissue Transglutaminase Assays
NCT05983978 ·Status: RECRUITING
-
Gluten Technology and Education for Celiac Health
NCT06059716 ·Status: RECRUITING ·Phase: NA
-
Choosing a Preferred Serology Kit for Screening and Diagnosis of Celiac Disease
NCT02805816 ·Status: COMPLETED
-
Serum Markers in Gluten Challenge
NCT00931892 ·Status: COMPLETED ·Phase: NA
-
A Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Celiac Disease
NCT02637141 ·Status: COMPLETED ·Phase: PHASE2
-
Anti-Tissue Transglutaminase IgA Antibodies
NCT04019223 ·Status: UNKNOWN
-
Evidence-based Screening Strategies for Celiac Disease
NCT03136731 ·Status: ENROLLING_BY_INVITATION
-
HLA-DQ2-gliadin Tetramer for Diagnosis of Celiac Disease
NCT01100099 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Intestinal Fatty Acid-binding Protein (I-FABP) Levels in Pediatric Celiac Patients
NCT03244254 ·Status: UNKNOWN
-
Effects of Home Gluten Immunogenic Peptide Testing on Children With Celiac Disease
NCT03462979 ·Status: SUSPENDED ·Phase: NA
-
Cardiovascular Risk Factors in Coeliac Disease: a Series of Studies
NCT05530070 ·Status: RECRUITING ·Phase: NA
-
Interpretation of Serological Tests in the Diagnosis of Celiac Disease: Anti-deamidated Gliadin Peptide Antibodies Revisited
NCT03320811 ·Status: COMPLETED
-
Latiglutenase as a Treatment for Celiac Disease
NCT03585478 ·Status: COMPLETED ·Phase: PHASE2